drugset / Trial / NCT01258348
A Phase 1b Trial in Patients With Renal Cell Cancer
SequentialOpen-labelTreatment
Summary
The purpose of this study is to determine a safe dose of LY573636-sodium to be given in combination with sunitinib to patients with metastatic Renal Cell Carcinoma (RCC) and to determine any side effects that may be associated with LY573636-sodium and sunitinib combination in this patient population. The tumor response rate will also be assessed.
Timeline
- Start
- 2008-07
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tasisulam | Small molecule | — | Intravenous |
| Background | Sunitinib | Small molecule | 37.5 mg | Oral |
| Background | Sunitinib | Small molecule | 50 mg | Oral |